Spectrum Pharmaceuticals, Inc. was added to the Russell 2000®, Russell 3000®, and the Russell Global® indexes on July 1, 2009. We are also a member of the Nasdaq Biotechnology Index.
Spectrum's transfer agent is Computershare and can be contacted at: Computershare Trust Company, N.A.
P.O. Box 43070
Providence, Rhode Island 02940-3070
Inside the US 800.962.4284
Outside the US 781.575.3210
The Annual Meeting of Stockholders typically takes place in the middle of each year. Further information regarding the date will be available on our website once the date has been set.
Spectrum currently has three drug candidates that are no longer under active development; SPI-339, SPI-376 and SPI-392. Spectrum still retains the intellectual property rights to these products, and intends to out-license these compounds if possible. Currently, there are no plans to resurrect these products into active development.